Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-001 in Recurrent and/or Metastatic Solid Tumours
NCT04823897Phase 1Recruiting
- Sponsor
- PharmaMatrix
- Start
- Jul 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cci-001 in solid tumor, sponsored by PharmaMatrix. Primary endpoints: Safety and Tolerability at 28 days and Recommended Expansion Dose at 28 days. Started Jul 2021; status: recruiting.
02
Drugs
cci-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04823897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823897.